Dr Obuli Ramachandran Nandhakumar · Vitreoretinal Surgeon, Delhi NCR
I operate on retinas, and on the economics of the hospitals around them.
I am a retina specialist and vitreoretinal surgeon at Centre for Sight in New Delhi and Gurugram. I work on health economics, healthcare strategy and AI in healthcare, and I advise hospitals, startups and investors as co-founder of Aavinyaa Strategies, a healthcare venture studio incubated at AIC NIFIE, IIM Mumbai.
I treat diseases of the retina, with surgery, injections and laser.
I am a retina specialist and vitreoretinal surgeon at Centre for Sight in New Delhi and Gurugram. I have performed more than 5,000 retina surgeries and 10,000 injections and laser procedures. This page tells you what I treat and how to book an appointment.
I read eye hospitals from the theatre and from the balance sheet.
I am a practising vitreoretinal surgeon and co-founder of Aavinyaa Strategies. I advise hospitals and investors on operations, due diligence and sector research, and I wrote a report on five years of accounts of India's eye hospital chains.
I help healthcare startups get from idea to clinic.
Through Aavinyaa Strategies I have evaluated more than 100 healthcare ventures. I advise founders on clinical validation, the CDSCO regulatory pathway, financial models and access to hospitals. I also evaluate AI products as a practising surgeon.
peer-reviewed publications across PubMed, EMBASE and Cochrane
100+
healthcare ventures evaluated through Aavinyaa Strategies
12
eye care businesses analysed from five years of audited accounts
4
cities where I helped build retina services
2
randomised trials co-authored
About
About Me
How I Came to Management
I was born in Salem, Tamil Nadu. My family are weavers from Singalandapuram, a small village near Rasipuram, and both my parents come from small villages. My father was the second graduate in our family and worked as a bank manager. His job came with frequent transfers, so I grew up across the country and studied in more than seven schools.
I studied medicine at Kilpauk Medical College, Chennai. Ophthalmology was not my first choice. I chose it because I had the chance to train at the Dr Rajendra Prasad Centre for Ophthalmic Sciences at AIIMS New Delhi, the apex institute of our country. My love for the retina started there. My senior residents kept us back until midnight, made us examine the retina with the indirect ophthalmoscope and taught us the findings. Those nights left an imprint on me.
I joined Aravind Eye Hospital, Madurai, in 2017 for my vitreoretinal fellowship and stayed on as a consultant until 2021. I now work at Centre for Sight in Delhi NCR. I have performed more than 5,000 vitreoretinal surgeries and 10,000 intravitreal injections and laser procedures.
My interest in management started at Aravind. I attended the monthly reviews and quality control meetings, worked in LAICO outreach camps, and did capstone projects with visiting MBA students from the United States. My head of department, Dr Naresh Babu, has an MBA, and that made me want to study management.
I completed the Advanced Management Programme in Healthcare at the Indian School of Business and was on the Dean's List. I then completed the FMVA certification in financial modelling and valuation. I co-founded Aavinyaa Strategies, a healthcare venture studio incubated at AIC NIFIE, IIM Mumbai.
I divide my week between surgery at Centre for Sight and my work at Aavinyaa Strategies. I write about healthcare economics for ophthalmologists because I want more doctors to understand financial statements.
Family
My wife, Dr Gauri Khare, is a vitreoretinal surgeon at Centre for Sight and a co-author on several of my papers. We live in Gurugram with our young daughter.
Outside Work
I collect automatic watches. I have suffered as a supporter ofever since Alex Ferguson left. I also follow the Los Angeles Lakers and CSK. I read history and listen to a curated list of podcasts.
With Gauri and our daughter at the Indian School of Business
Surgeon and venture builder
Why I Do Both
I am a practising vitreoretinal surgeon. I have performed more than 5,000 retina surgeries, trained fellows, examined for national boards and published more than 30 papers.
I give part of my week to Aavinyaa Strategies, a doctor-led healthcare venture studio, because I want hospitals and healthcare startups to deliver better care to more patients. I work with hospital owners on how their centres run, and with founders on proving that their products work in a real clinic.
Career
Work and Achievements
My training and work at AIIMS, Aravind Eye Hospital, Centre for Sight and Aavinyaa Strategies.
Chapter One
AIIMS
Dr Rajendra Prasad Centre for Ophthalmic Sciences, AIIMS New Delhi. MD Ophthalmology, 2013 to 2016.
Performed more than 100 phacoemulsification surgeries as a resident
Independently managed the trauma theatre and the eye casualty
Performed lid surgery, dacryocystorhinostomy, trabeculectomy and corneal transplants
Performed vitrectomies for endophthalmitis
Thesis on oral steroids in paediatric orbital cellulitis, with a comparison of treatment response in adults. We found meaningful improvement when steroids were started together with intravenous antibiotics
With my MD degree at the 45th AIIMS convocation, January 2018
Chapter Two
Aravind
Aravind Eye Hospital, Madurai. Vitreoretinal Fellow, 2017 to 2019. Consultant, 2019 to 2021.
About 2,500 vitreoretinal surgeries in two and a half years, and more than 6,000 intravitreal injections and laser procedures
Vitreoretinal fellowship (FVRS) under Dr Naresh Babu
Surgery for retinal detachment, including cases with proliferative vitreoretinopathy, choroidal detachment and coloboma
Macular hole surgery, diabetic vitrectomy, scleral-fixated intraocular lenses, ocular trauma and 3-D heads-up surgery
As a consultant, headed my own operating day
Conducted masterclasses on scleral-fixated IOLs and diabetic vitrectomy
Presented at journal clubs and took classes for postgraduate residents
Co-author of two randomised trials: platelet-rich plasma against the inverted ILM flap for large macular holes, and intravitreal methotrexate in proliferative vitreoretinopathy
Worked with Google Research on AI screening for diabetic retinopathy
Outreach camps with LAICO, quality control meetings, and capstone projects with visiting MBA students from the United States
With Dr Naresh BabuSurgical training in the operating theatre at AravindOutreach camp visit, Rameswaram
Chapter Three
Centre for Sight
Centre for Sight Eye Institute, Delhi NCR. Associate Consultant, 2021 to 2024. Consultant Vitreoretinal Surgeon and Fellowship Co-Incharge, 2024 to present.
More than 2,500 vitreoretinal surgeries and 4,000 intravitreal injections and laser procedures
Eyeconic 2025 award for the highest number of vitreoretinal surgeries in the organisation in FY 2024 to 25
Helped build retina services in Agra, Hisar, Gurugram and Ranchi, and raised surgical capacity at Gurugram and Safdarjung Enclave
Surgical trainer for vitreoretinal fellows and Fellowship Co-Incharge
External examiner, invited by the National Board of Examinations, for the FNB Vitreoretina exit examination
Examiner for the FAICO examination of the All India Ophthalmological Society
Started and led process improvement and optimisation projects across the organisation
Led the organisation's evaluation of multiple AI products for ophthalmology
Site investigator for an aflibercept biosimilar clinical trial
Centre for SightWith senior colleagues at Centre for SightWith the team at Centre for Sight
Chapter Four
Aavinyaa Strategies
Aavinyaa Strategies, a doctor-led healthcare venture studio, 2025 to present. Co-founder and VP, Strategy and Operations. I co-founded it with colleagues from the ISB Advanced Management Programme in Healthcare, and I do this work alongside my surgical practice at Centre for Sight.
Startups. I have evaluated more than 100 healthcare ventures. I advise founders on clinical validation, the CDSCO regulatory pathway, investor-ready financial models and market access through partner hospitals
Clinics, diagnostics and hospitals. I work with owners on throughput, ARPOB, occupancy, revenue cycle and denial reduction, and on site feasibility and expansion models for multi-location growth
Investors. I carry out clinical and operational due diligence for venture capital, private equity and angel investors, and I write sector and equity research on Indian healthcare
Incubators and CSR funders. I screen cohorts and mentor founders for incubators, and I help CSR funders design and verify healthcare projects
The All India Ophthalmological Society invited Aavinyaa Strategies to be its innovation partner
Expert network. Network Member at GLG since June 2026, covering healthcare, ophthalmology and AI in healthcare
Aavinyaa Strategies operates as Moonshot Advisory Private Limited and is incubated at AIC NIFIE, IIM Mumbai
Advanced Management Programme in Healthcare, Indian School of Business, Dean's List
Financial Modelling and Valuation Analyst, Corporate Finance Institute
Aavinyaa Strategies, innovation partner of the All India Ophthalmological Society. AIOC 2026, JaipurISB graduation, 2025
Expertise
Areas of Expertise
What I Treat
Work With Hospitals and Investors
Work With Startups
My work covers four areas: retina surgery, health economics in ophthalmology, healthcare strategy, and AI in healthcare.
Retina and Vitreoretinal Surgery
I am a retina specialist and vitreoretinal surgeon in Delhi NCR. I operate at Centre for Sight hospitals in New Delhi and Gurugram and treat medical and surgical diseases of the retina.
Pars plana vitrectomyRetinal detachment surgeryScleral bucklingMacular hole surgery with ILM peelingDiabetic vitrectomyAnti-VEGF injectionsOzurdex implantRetinal laserScleral-fixated and glued IOL
Health Economics in Ophthalmology
I study what eye treatments cost in India and what patients gain from them. I use cost-utility analysis, real-world evidence and systematic reviews.
Research subjects
Cost-effectiveness of anti-VEGF therapyAflibercept, ranibizumab and biosimilarsTreatment burden in diabetic macular oedemaValue-based care in eye hospitalsAI screening for diabetic retinopathyValidation of indigenous medical devices
Methods
Cost-utility analysisHealth economics and outcomes researchReal-world evidenceSystematic review and meta-analysisRandomised controlled trials
Healthcare Consulting and Strategy
Through Aavinyaa Strategies I advise eye hospitals, healthcare startups and investors in India. I combine surgical practice with training in management and finance.
Work for hospitals and clinics
Eye hospital operationsRetina service set-upHub and spoke network designRevenue cycle and denial reductionSite feasibility and expansionFinancial literacy for doctors
Work for startups and investors
Clinical validationEvaluation of clinical AI productsCDSCO regulatory pathwayClinical and operational due diligenceSector and equity researchIndian eye care market analysisFinancial modelling and valuation
AI in Healthcare
I have worked with clinical AI in three roles: as a researcher, as the person who evaluates AI products for a hospital group, and as an adviser to startups and investors. I help hospitals and practices decide which AI tools to adopt and how to bring them into daily clinical work.
My experience
Worked with Google Research on AI screening for diabetic retinopathy during my fellowship at Aravind Eye Hospital, 2017 to 2019
Led Centre for Sight's evaluation of multiple AI products for ophthalmology
Advise healthcare startups on clinical validation and the CDSCO regulatory pathway through Aavinyaa Strategies
Panelist on AI in healthcare in 2026, representing Centre for Sight
Implementation work
Selection and evaluation of AI productsClinical validation and review of evidenceFitting AI into clinic and operating theatre workflowRegulatory pathway for AI as a medical deviceCost and return on AI toolsTraining and adoption by doctors and staffHuman oversight of AI in patient care
Recognition
Awards, Examiner Roles and Degrees
Awards and Recognition
2023
Asia's Best Surgical Video, APVRS
Awarded at the Asia-Pacific Vitreo-retina Society congress in Hong Kong.
2025 and 2026
Best Video Award, SFO Session, AIOS
Won in two consecutive years at the annual conference of the All India Ophthalmological Society.
With the trophy at the AIOS annual conference
Multiple years
Best Video Award, Ophthalmic Premier League
Won more than once at the Ophthalmic Premier League of the All India Ophthalmological Society.
Eyeconic 2025 certificate
2025
Eyeconic Award, Centre for Sight
For the highest number of vitreoretinal surgeries in the organisation in FY 2024 to 25, and for building retina services across several centres.
ISB graduation, 2025
ISB
Dean's List, Indian School of Business
Advanced Management Programme in Healthcare. Awarded to the top five of the cohort.
2020
Best Poster in Vitreo Retina, TNOA
Tamil Nadu Ophthalmic Association annual conference.
Examiner and Reviewer Roles
Review
Peer ReviewerReviewer for national and international journals. I have reviewed more than 30 papers for publication.
NBE
External Examiner, FNB VitreoretinaInvited by the National Board of Examinations for the fellowship exit examination.
AIOS
Examiner, FAICOExaminer for the Fellowship of the All India Collegium of Ophthalmology.
Training
Surgical TrainerTrainer for vitreoretinal fellows and Fellowship Co-Incharge at Centre for Sight.
Examining at the FAICO examination
Degrees and Fellowships
6/60MD
6/36MRCS (Ed)
6/24FVRS · FAICO · FICO
6/12AMPH · FMVA
6/9AIIMS · Aravind · Royal College of Surgeons of Edinburgh · ISB · CFI
6/6If you can read this line, your macula is doing its job.
Clinic and research
OCT and Cost-Effectiveness Analysis
I use two kinds of chart in my work. In clinic I read OCT scans of the macula. In research I use cost-effectiveness analysis to compare treatments.
250 ┬╡m
Plate I. The macula on optical coherence tomographyMove the cursor across the scan to measure retinal thickness. This is a drawing made in code and is not a patient scan.
Health economics
The Cost-Effectiveness Plane
Each point is one simulated comparison of a new treatment with the current standard. Points further right add more health. Points higher up cost more. The dashed line is the most a payer will spend for one year of good health. A treatment is cost-effective when most of the points fall below that line.
I am building this analysis for the treatments of diabetic macular oedema in India.
Plate II. The cost-effectiveness planeIllustration with simulated points.
Research
Papers, Essays and Presentations
Sector report 2026-27
Five Years of Financials of India's Major Eye Care Chains and Hospitals
I studied the audited accounts of twelve eye care businesses from FY22 to FY26. The report has its own page with an interactive timeline and charts.
Real-world efficacy of higher-dose aflibercept in pro-re-nata dosing without loading phasesFirst author. Indian J Ophthalmol. 74(11):1714-1719. 194 eyes, 22.6% fewer annual visits, 8.52 hours saved per patient per year. DOI
2026
Long-term analysis of intravitreal brolucizumab in chronic central serous retinopathy with neovascularizationIndian J Ophthalmol. 74(6):893-900. DOI
2026
Peep into anti-vascular endothelial growth factorReview. Indian J Ophthalmol. 74(5):635-638. DOI
Now
Work in progressCost-utility analysis of treatments for diabetic macular oedema in India. PROSPERO-registered systematic review of endophthalmitis after cataract surgery.
Essays and Sector Writing
2026
The Retina GapEssay on the distance between the retina care India needs and the care it delivers, built from public filings and Aravind's activity reports since 2000.
2026
The Retina DriftEssay drawn from interviews with 23 retina surgeons on how their practices have changed.
2026
NMC Advertising Guidelines 2026, in Four PartsSeries on what the guidelines of 6 October 2026 mean for doctors, hospitals and the investors who fund them.
Real-world efficacy of higher-dose aflibercept in pro-re-nata dosing without loading phases: A cost-effective approach for resource-limited settingsIndian J Ophthalmol. DOI
2026
Long-term analysis of intravitreal brolucizumab in recalcitrant cases of chronic central serous retinopathy complicated by neovascularization (pachychoroid neovasculopathy)Indian J Ophthalmol. DOI
2026
Peep into anti-vascular endothelial growth factorIndian J Ophthalmol. DOI
2026
Historical trends in vitreoretinal care: The evolving landscape in North IndiaIndian J Ophthalmol. DOI
2025
Intravitreal methotrexate as an adjuvant in vitrectomy in cases of retinal detachment with proliferative vitreoretinopathyGraefes Arch Clin Exp Ophthalmol. DOI
2024
Short-term postoperative perfluorocarbon liquid-silicone oil combination tamponade for chronic rhegmatogenous retinal detachment: Initial experienceIndian J Ophthalmol. DOI
2022
Frosted branch angiitis following corneal tear repairTaiwan J Ophthalmol. DOI
2021
Two-staged surgery as an alternative to buckle-vitrectomy for rhegmatogenous retinal detachment complicated by choroidal detachmentInt Ophthalmol. DOI
2021
Abnormal retinal vasculature in a young child: a diagnostic dilemmaOcul Immunol Inflamm.
2020
Comparison of platelet-rich plasma and inverted internal limiting membrane flap for the management of large macular holes: A pilot studyIndian J Ophthalmol. DOI
2020
Multimodal imaging-guided diagnosis, management and follow-up of a case of diffuse unilateral subacute neuroretinitisBMJ Case Rep. DOI
2020
Comment on: Clinical presentations and comparative outcomes of primary versus deferred intraocular lens explantation in delayed.onset endophthalmitisIndian J Ophthalmol. DOI
2020
Management of coexistent choroidal neovascular membrane and macular hole with serous detachment in a case of pathological myopia: challenges and dilemmasBMJ Case Rep. DOI
2020
Clinical Spectrum and Long-Term Anatomical and Functional Outcomes of Pars Plana Vitrectomy in Retinal Detachments Associated With Choroidal ColobomaJ Vitreoretin Dis. DOI
2019
Rare cause of floaters: A motile live worm in vitreous cavityIndian J Ophthalmol. DOI
2018
Comparison of surgical performance of internal limiting membrane peeling using a 3-D visualization system with conventional microscopeOphthalmic Surg Lasers Imaging Retina.
ASRS Annual MeetingExpert panel presentation at the American Society of Retina Specialists: "Platform Matters? Comparative Effectiveness of 5 Vitrectomy Systems in 1,082 Primary Vitreoretinal Surgeries".
2026
ARVO Annual MeetingPoster on the pooled prevalence of dry eye disease, 31.8%. Abstract 446317.
2026
Saudi Retina Symposium, JeddahInvited presentation.
2025
MEOM, DubaiInvited speaker.
2021 to 2026
All India Ophthalmological Society Annual ConferenceInvited speaker in 2021, 2022, 2024, 2025 and 2026. In 2026 I spoke on the glued IOL in the instruction course on scleral-fixated lenses.
2022 to 2025
EURETINASurgical videos invited in 2022, 2023 and 2025.
2023
APVRS, Hong KongSurgical video presentation. Won Asia's Best Surgical Video.
Ongoing
Invited Industry TalksSpeaker for Novartis, AbbVie, Sun Pharma and Reliance Life Sciences on my experience with anti-VEGF therapy and Ozurdex.
2026
Panel on AI in HealthcarePanelist representing Centre for Sight.
2026
Aravind Golden Jubilee Reunion Meet, MaduraiAlumni talk, December.
I am Dr Obuli Ramachandran Nandhakumar, a consultant vitreoretinal surgeon at Centre for Sight in Delhi NCR. I trained at AIIMS New Delhi and Aravind Eye Hospital, Madurai. I have performed more than 5,000 vitreoretinal surgeries and 10,000 intravitreal injections and laser procedures. I am also the co-founder of Aavinyaa Strategies, a healthcare venture studio.
Where does Dr Obuli Ramachandran see retina patients, and how do I book an appointment?
I see retina patients at Centre for Sight hospitals in Delhi NCR, including New Delhi and Gurugram. To book an appointment, call Centre for Sight on 011-42504250.
Which retinal conditions does he treat?
I treat retinal detachment, diabetic retinopathy, diabetic macular oedema, macular hole, epiretinal membrane, vitreous haemorrhage, age-related macular degeneration, retinal vein occlusion, central serous chorioretinopathy, endophthalmitis and eye injuries that involve the retina.
What is a vitrectomy, and when is it needed?
A vitrectomy is an operation in which I remove the vitreous gel from inside the eye through three small openings. It is done for retinal detachment, macular hole, bleeding inside the eye from diabetes, and infection inside the eye.
How urgent is a retinal detachment?
A retinal detachment is an emergency. New flashes of light, a sudden shower of floaters or a dark curtain across part of your vision need a retina examination on the same day. Surgery works best before the centre of the retina detaches.
What are intravitreal injections used for?
I inject anti-VEGF medicines or a steroid implant into the eye to treat diabetic macular oedema, wet age-related macular degeneration and retinal vein occlusion. The procedure takes a few minutes under anaesthetic drops.
How often should a person with diabetes have a retina examination?
A person with diabetes needs a retina examination once a year while the retina is normal, and more often once diabetic retinopathy is found.
What health economics research does he do in ophthalmology?
I study what eye treatments cost and what patients gain from them. My published work includes a study of higher-dose aflibercept that reduced clinic visits by 22.6%. I am building a cost-utility analysis of treatments for diabetic macular oedema in India.
Does he advise eye hospitals, healthcare startups and investors?
Yes. Through Aavinyaa Strategies I advise healthcare startups on clinical validation and regulatory approval, work with clinic and hospital owners on operations and expansion, and carry out clinical and operational due diligence for venture capital, private equity and angel investors. I have evaluated more than 100 healthcare ventures.
What is the Sector Report 2026-27?
It is my study of five years of audited financial statements of twelve Indian eye care chains and hospitals, from FY22 to FY26. It covers market size, government scheme rates, return on capital, valuation multiples and predictions to 2030.
How do I invite Dr Obuli Ramachandran to speak or collaborate?
Write to me at the address in the Contact section. I speak on vitreoretinal surgery, anti-VEGF therapy, health economics in ophthalmology and AI in eye care.
Gallery
Photographs
Photographs from work, conferences and home.
On the main stage at ASRS 2026Speaking at the Saudi Retina Symposium, Jeddah, 2026On a conference panelAt a conference
Clinic
A Fundus, Annotated
Six findings I look for when I examine the retina. Choose a number to read about each one.
1 of 6
What it is
Usual cause
What I do
This is a teaching drawing that combines findings from different diseases.
Contact
Enquiries and Appointments
Appointments
Enquiries
Professional enquiries
Advisory roles, health economics and outcomes research, clinical validation, speaking and collaborations.
If I have treated you, you can write about your experience on the Google page of Centre for Sight, Safdarjung Enclave. Please mention Dr Obuli Ramachandran, so that the hospital knows who treated you.
Sector report 2026-27 · Created by Dr Obuli Ramachandran Nandhakumar
Five Years of Financials of India's Major Eye Care Chains and Hospitals
This page summarises my report Inside India's Private Eye Hospital Chains, Edition 2. I studied the audited accounts of twelve eye care businesses from FY22 to FY26 and compared them with the market they work in. I led the research and wrote the notes in the margins. Point at anything marked with a dot to read them.
Rs 37,800 croreThe Indian eye care market in FY24. It has grown 11.5% a year since FY19
14 to 16 millionCataract operations a year, more than any other country
15 per millionOphthalmologists in India. High income countries average 76
13 to 15%Share of the market held by chains in FY24
Rs 5,849 croreRevenue of the twelve businesses in the report, 15.5% of the FY24 market
80 to 85%Share of eye care revenue that comes from surgery
History and predictions
Timeline, 2002 to 2030
Drag the slider from 2002 to 2030. Each stop is marked as a filed fact, a third party projection or my prediction.
2002Filed fact
My note
Payers
Government Scheme Rates
These are the rates government schemes pay hospitals. Each bar runs from the lowest to the highest published rate, in rupees.
Sources: CGHS schedule for Delhi NCR, RSBY 2018 package, and published summaries of the Ayushman Bharat PM-JAY 2022 package master.
Capital
Return on Capital
Each outer square shows the capital employed, drawn to scale. The inner square shows the operating profit earned on it in a year.
7.0%Three private equity backed consolidators earn Rs 225 crore of EBIT on Rs 3,220 crore of capital
33.2%Three founder led chains earn Rs 214 crore of EBIT on Rs 645 crore of capital
Valuation
Valuation Multiples
These are the prices paid for eye care businesses, as a multiple of yearly EBITDA. Drag the slider to see who paid each price.
9.0x
My note
The charitable institutions
Surgical Volumes
Surgical volume in the latest reported year. The charitable institutions set the price of cataract surgery and the pay of surgeons across south India.
The full report
Full Report
The full report has 63 pages, 24 exhibits and 27 tables. It covers eleven company profiles, the partner surgeon model, receivables, the history of Vasan Eye Care, and ten predictions. Write to me for a copy.